Stroke is a devastating complication of transcatheter aortic-valve implantation (TAVI), compromising its remarkable ...

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Intracranial aneurysms are common, and the risk of rupture is influenced by size, location, morphology, and factors such as ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

We conducted a phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial that included 11 groups as two cohorts. Participants with obesity (obesity cohort) were randomly assigned ...

One of the more difficult decisions for patients with poorly controlled type 2 diabetes, as well as for their clinicians, is ...

A total of 415 patients were assigned to cemiplimab (209) or placebo (206). The median follow-up was 24 months. Cemiplimab was superior to placebo with respect to disease-free survival (24 vs. 65 ...

Among 485 patients who were MRD-negative at 10 −5 sensitivity after induction, a premaintenance MRD-negative status at 10 −6 sensitivity occurred in 86% in the ASCT group and in 84% in the Isa ...

Vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) estrogen receptor (ER) degrader that directly harnesses the ubiquitin–proteasome system.In this phase 3, open-label, randomized ...

As physicians continue to debate the role of race in clinical algorithms, the unusual history of debates over race-specific anemia diagnosis may be instructive.

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer.